Literature DB >> 17636119

Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis.

Arie Gruzman1, William L Wood, Evgenia Alpert, M Dharma Prasad, Robert G Miller, Jeffery D Rothstein, Robert Bowser, Ronald Hamilton, Troy D Wood, Don W Cleveland, Vishwanath R Lingappa, Jian Liu.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating motor neuron degenerative disease whose etiology and pathogenesis remain poorly understood. Most cases of ALS ( approximately 90%) are sporadic (SALS), occurring in the absence of genetic associations. Approximately 20% of familial ALS (FALS) cases are due to known mutations in the copper, zinc superoxide dismutase (SOD1) gene. Molecular evidence for a common pathogenesis of SALS and FALS has remained elusive. Here we use covalent chemical modification to reveal an attribute of spinal cord SOD1 common to both SOD1-linked FALS and SALS, but not present in normal or disease-affected tissues from other neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's diseases and spinal muscular atrophy, a non-ALS motor neuron disease. Biotinylation reveals a 32-kDa, covalently cross-linked SOD1-containing protein species produced not only in FALS caused by SOD1 mutation, but also in SALS. These studies use chemical modification as a novel tool for the detection of a disease-associated biomarker. Our results identify a shared molecular event involving a known target gene and suggest a common step in the pathogenesis between SALS and FALS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17636119      PMCID: PMC1941502          DOI: 10.1073/pnas.0705044104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

Review 1.  From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS.

Authors:  D W Cleveland; J D Rothstein
Journal:  Nat Rev Neurosci       Date:  2001-11       Impact factor: 34.870

2.  Common denominator of Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis: decreased stability of the apo state.

Authors:  Mikael J Lindberg; Lena Tibell; Mikael Oliveberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

3.  Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase.

Authors:  A G Estévez; J P Crow; J B Sampson; C Reiter; Y Zhuang; G J Richardson; M M Tarpey; L Barbeito; J S Beckman
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

4.  Superoxide dismutase gene mutations in Italian patients with familial and sporadic amyotrophic lateral sclerosis: identification of three novel missense mutations.

Authors:  C Gellera; B Castellotti; M C Riggio; V Silani; L Morandi; D Testa; C Casali; F Taroni; S Di Donato; M Zeviani; C Mariotti
Journal:  Neuromuscul Disord       Date:  2001-05       Impact factor: 4.296

5.  Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1.

Authors:  D Jaarsma; E D Haasdijk; J A Grashorn; R Hawkins; W van Duijn; H W Verspaget; J London; J C Holstege
Journal:  Neurobiol Dis       Date:  2000-12       Impact factor: 5.996

6.  High molecular weight complexes of mutant superoxide dismutase 1: age-dependent and tissue-specific accumulation.

Authors:  Jiou Wang; Guilian Xu; David R Borchelt
Journal:  Neurobiol Dis       Date:  2002-03       Impact factor: 5.996

7.  Amyloid-like filaments and water-filled nanotubes formed by SOD1 mutant proteins linked to familial ALS.

Authors:  Jennifer Stine Elam; Alexander B Taylor; Richard Strange; Svetlana Antonyuk; Peter A Doucette; Jorge A Rodriguez; S Samar Hasnain; Lawrence J Hayward; Joan Selverstone Valentine; Todd O Yeates; P John Hart
Journal:  Nat Struct Biol       Date:  2003-06

8.  Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation.

Authors:  Samer Abou Ezzi; Makoto Urushitani; Jean-Pierre Julien
Journal:  J Neurochem       Date:  2007-03-29       Impact factor: 5.372

9.  Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis.

Authors:  Rishi Rakhit; Patricia Cunningham; Alexandra Furtos-Matei; Sophie Dahan; Xiao-Fei Qi; John P Crow; Neil R Cashman; Leslie H Kondejewski; Avijit Chakrabartty
Journal:  J Biol Chem       Date:  2002-09-27       Impact factor: 5.157

10.  Molecular analysis of the superoxide dismutase 1 gene in Spanish patients with sporadic or familial amyotrophic lateral sclerosis.

Authors:  A García-Redondo; F Bustos; B Juan Y Seva; P Del Hoyo; S Jiménez; Y Campos; M A Martín; J C Rubio; F Cañadillas; J Arenas; J Esteban
Journal:  Muscle Nerve       Date:  2002-08       Impact factor: 3.217

View more
  88 in total

1.  Mutant SOD1 forms ion channel: implications for ALS pathophysiology.

Authors:  Michael J Allen; Jérome J Lacroix; Srinivasan Ramachandran; Ricardo Capone; Jenny L Whitlock; Ghanashyam D Ghadge; Morton F Arnsdorf; Raymond P Roos; Ratnesh Lal
Journal:  Neurobiol Dis       Date:  2011-09-10       Impact factor: 5.996

Review 2.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

3.  Nonamyloid aggregates arising from mature copper/zinc superoxide dismutases resemble those observed in amyotrophic lateral sclerosis.

Authors:  Young-Mi Hwang; Peter B Stathopulos; Kristin Dimmick; Hong Yang; Hamid R Badiei; Ming Sze Tong; Jessica A O Rumfeldt; Pu Chen; Vassili Karanassios; Elizabeth M Meiering
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

Review 4.  RNA-targeted Therapeutics for ALS.

Authors:  Linga V Reddy; Timothy M Miller
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 5.  Motor neuron trophic factors: therapeutic use in ALS?

Authors:  Thomas W Gould; Ronald W Oppenheim
Journal:  Brain Res Rev       Date:  2010-10-21

Review 6.  Novel therapeutic targets in neurodegenerative diseases: lessons from amyotrophic lateral sclerosis.

Authors:  Stanley H Appel; David R Beers; Jenny S Henkel; Weihua Zhao
Journal:  Curr Neurol Neurosci Rep       Date:  2008-09       Impact factor: 5.081

7.  Wild-type SOD1 overexpression accelerates disease onset of a G85R SOD1 mouse.

Authors:  Lijun Wang; Han-Xiang Deng; Gabriella Grisotti; Hong Zhai; Teepu Siddique; Raymond P Roos
Journal:  Hum Mol Genet       Date:  2009-02-19       Impact factor: 6.150

8.  Mistranslation-induced protein misfolding as a dominant constraint on coding-sequence evolution.

Authors:  D Allan Drummond; Claus O Wilke
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

9.  Moderate exercise delays the motor performance decline in a transgenic model of ALS.

Authors:  Isabel Carreras; Sinan Yuruker; Nurgul Aytan; Lokman Hossain; Ji-Kyung Choi; Bruce G Jenkins; Neil W Kowall; Alpaslan Dedeoglu
Journal:  Brain Res       Date:  2009-12-05       Impact factor: 3.252

Review 10.  Physical activity and neuroprotection in amyotrophic lateral sclerosis.

Authors:  Mary E McCrate; Brian K Kaspar
Journal:  Neuromolecular Med       Date:  2008-02-20       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.